title: Crosstalk between insulin and dopamine signaling: A basis for the metabolic effects of antipsychotic drugs.
abstract: In the setting of rising rates of obesity and metabolic syndrome, characterized in part by hyperinsulinemia, it is increasingly important to understand the mechanisms that contribute to insulin dysregulation. The higher risk for metabolic syndrome imparted by antipsychotic medication use highlights one such mechanism. Though there is great variation in the number and types of signaling pathways targeted by these medications, the one common mechanism of action is through dopamine. Dopamine's effects on insulin signaling begin at the level of insulin secretion from the pancreas and continue through the central nervous system. In a reciprocal fashion, insulin also affects dopamine signaling, with specific effects on dopamine reuptake from the synapse. This review probes the dopamine-insulin connection to provide a comprehensive examination of how antipsychotics may contribute towards insulin resistance.
authors.affiliation: National Institutes of Health, National Institute of Mental Health, Bethesda, MD 20892, United States. Electronic address: abigail.nash@nih.gov.
authors.forename: Abigail I
authors.initials: AI
authors.lastname: Nash
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000139:chemically induced; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D007328:Insulin; D004298:Dopamine
keywords: Antipsychotic; DAT; Dopamine; Hyperinsulinemia; Insulin; Schizophrenia